China’s National Medical Products Administration (NMPA) has approved ViiV Healthcare’s Vocabria (cabotegravir injection) used along with the Janssen Pharmaceutical Companies of Johnson ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...

Prior to starting Apretude injections, your health care provider may first prescribe you cabotegravir tablets, also known as Vocabria, for approximately one month to determine if you can tolerate ...

An estimated 13,000 people in England could make the switch. Cabotegravir (also called Vocabria and made by ViiV Healthcare) and rilpivirine (also called Rekambys and made by Janssen) are given as ...

They have been engineered to stay in the body after injection for at least two months. In Europe, long-acting cabotegravir is marketed under the name Vocabria. Long-acting rilpivirine is marketed ...

Patients in need can either start their treatment with Apretude or take oral cabotegravir (Vocabria) for four weeks to understand how well they can tolerate the drug. GSK is a key competitor for ...